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AbstrACt
Objective To actively solicit adverse events experienced 
in the days following immunisation with quadrivalent 
inactivated influenza vaccine using Australia’s near real-
time, participant-based vaccine safety surveillance system, 
AusVaxSafety.
Design and setting Observational cohort study 
conducted in 194 sentinel surveillance immunisation sites 
(primary care, hospital and community-based clinics) 
across Australia.
Participants Individuals aged ≥6 months who received a 
routine seasonal influenza vaccine at a participating site 
(n=102 911) and responded to a survey (via short message 
service or email) sent 3 days after vaccination about 
adverse events experienced (n=73 892; 71.8%).
Main outcome measure Near real-time and cumulative 
participant-reported rates of any adverse event, fever 
or medical attendance experienced within 3 days after 
vaccination overall, by brand, age, pregnancy status and 
concomitant vaccine receipt.
results Participant median age was 57 years (range: 6 
months to 102 years); 58.1% (n=42 869) were female and 
2.7% (n=2018) were pregnant. Near real-time fast initial 
response cumulative summation and Bayesian analyses 
of weekly event rates did not demonstrate a safety signal. 
Children aged 6 months to 4 years had higher event rates 
(522/6180; 8.4%) compared with older ages; participants 
aged ≥65 years reported fewer events (1695/28 154; 
6.0%). There were no clinically significant differences 
in safety between brands, by age group or overall. 
Cumulative data analysis demonstrated that concomitant 
vaccination was associated with increased rates of fever 
(2.1% vs 0.8%) and medical attendance (0.8% vs 0.4%), 
although all rates were low and did not exceed expected 
levels.
Conclusions Novel, postmarketing AusVaxSafety 
surveillance demonstrated comparable and expected 
safety outcomes for the 2017 quadrivalent inactivated 
influenza vaccine brands used in Australia. These near 
real-time, participant-reported data are expected to 
encourage confidence in vaccine safety and promote 
uptake.
IntrODuCtIOn  
Influenza vaccines are given to hundreds of 
millions of people within short, fixed periods 
of time worldwide each year.1 This widespread 
use, coupled with the high degree of influenza 
vaccine variability, including multiple vaccine 
types (live, inactivated, subunit or adju-
vanted), manufacturing processes (in eggs, 
cell lines or with recombinant techniques) 
and strain compositions (trivalent or quadri-
valent, with the potential for vaccine viruses to 
change twice yearly across the Southern and 
Northern Hemisphere seasons), underscores 
the need for timely postmarketing vaccine 
safety surveillance. The European Medi-
cines Agency (EMA) now requires manufac-
turers to address the paucity of clinical trial 
safety data available for vaccine changes by 
strengths and limitations of this study
 ► A large number of vaccinated individuals of all ages 
across Australia participated, leading to a greater 
ability to detect serious adverse events.
 ► Comprehensive data enabled analysis of adverse 
events with respect to age, pregnancy, vaccine 
brand and concomitant vaccination with a wide va-
riety of vaccines.
 ► Safety signal detection was conducted in near real 
time using multiple statistical methods, with results 
reported to the public each week.
 ► Individuals participating in active surveillance may 
be less inclined to report common and expected 
reactions, limiting the ability to compare reported 
adverse event rates with those from clinical trials.
 ► Some outcomes of vaccine safety, such as partic-
ipant-reported fever, are subjective and have not 
been verified.
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conducting enhanced postmarketing safety surveillance 
for seasonal influenza vaccines.2 
AusVaxSafety, an automated, active vaccine safety 
surveillance system, reports near real-time, brand-specific 
data independent of manufacturers using participant-re-
ported outcomes. AusVaxSafety was established to improve 
vaccine safety monitoring following recommendations of 
an independent inquiry into the unprecedented increase 
in febrile seizures observed in young Australian children 
in 2010, ultimately determined to be associated with one 
influenza vaccine brand (Fluvax/Afluria; bioCSL).3 This 
incident, which led to temporary nationwide suspension 
of paediatric influenza immunisation, resulted in a loss of 
confidence in influenza vaccines among consumers and 
immunisation providers and decreased influenza vaccine 
uptake.4 5
From 2014 to 2016 AusVaxSafety conducted influenza 
vaccine safety surveillance in 8184 children aged 6 months 
Figure 1 Counts of enrollees and participants by epidemiological week and age group or pregnancy status (A: 6 months to 
4 years; B: 5–64 years; C: ≥65 years; D: Pregnant). Each bar displays the number of participants (dark grey) out of the total 
number of enrollees (light grey) for each week.
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to 4 years.6 7 A retrospective analysis comparing safety 
profiles of trivalent inactivated influenza vaccine (TIIV) 
and quadrivalent inactivated influenza vaccine (QIIV) 
brands in 2015 and 2016 demonstrated that concomitant 
vaccine administration in young children was associated 
with increased fever and medical attendance (MA) rates 
after vaccination, although rates were low and within 
expected ranges.7 Importantly, detailed follow-up data on 
the small number of children who sought medical atten-
tion showed no serious or unexpected vaccine-associated 
adverse events following immunisation (AEFI).
In 2017, AusVaxSafety surveillance expanded to include 
influenza vaccine recipients of all ages. Here we provide 
an overview of AusVaxSafety’s weekly surveillance and a 
detailed analysis of cumulative (end of vaccine season) 
safety data by QIIV brand, age, pregnancy status and 
concomitant vaccine receipt.
MethODs
AusVaxsafety active vaccine safety surveillance
Surveillance included individuals aged ≥6 months who 
received a 2017 seasonal influenza vaccine between 1 April 
and 31 August 2017 at one of 194 participating immuni-
sation providers across Australia, including general prac-
tices, hospitals, community-based clinics and Aboriginal 
Medical Services. Annual influenza vaccination is recom-
mended for all individuals aged 6 months and older 
who wish to protect themselves from influenza, but it is 
funded (available for free) under the Australian National 
Immunisation Program (NIP) for groups at increased risk 
of complications from influenza. These include individ-
uals aged 65 years and older; Aboriginal and Torres Strait 
Islander people aged 6 months to 4 years and 15 years 
and older; pregnant women; and anyone 6 months and 
older who has a medical condition (including heart or 
lung disease, asthma, chronic neurological conditions, 
immune compromising conditions or other chronic 
illnesses such as diabetes).8 In 2017, one state (Western 
Australia) also funded influenza vaccine for all children 
aged 6 months to 4 years.
Most individuals were enrolled using the opt-out, 
computer-based monitoring platform SmartVax, which 
integrates with immunisation provider management soft-
ware to issue automated surveys to vaccine recipients or 
their caregivers via short message service (SMS), as previ-
ously described.9 A minority of AusVaxSafety sites (n=30) 
used one of two alternative computer-based monitoring 
platforms—Vaxtracker10 (recipients aged 6 months to 4 
years only) or Stimulated Telephone-Assisted Rapid Safety 
Surveillance (STARSS)11—to solicit influenza vaccine 
adverse events following opt-in enrolment.
Vaccinated individuals/caregivers received an SMS 
from their medical provider 3 days after vaccination 
inquiring about AEFI (‘We would like to know if there 
were any reactions to the vax. Please reply with JUST a Y 
or N.’). Those who responded ‘Y’ or ‘N’ were classified 
as participants, and those who responded ‘Y’ were then 
Table 1 Descriptive variables of 73 892 participants in 
AusVaxSafety’s 2017 influenza vaccine safety surveillance
Variable Description n (%)
Sex* Male 30 968 (41.9)
Female 42 869 (58.1)
Indigenous status† Aboriginal 1000 (1.7)




Age median (IQR; range) 57 years (31–69 years; 6 months to 102 years)
Age group 6 months to 4 years 6180 (8.4)
5–14 years 4415 (6.0)
15–39 years 13 434 (18.2)
40–64 years 21 709 (29.4)
≥65 years 28 154 (38.1)



















Typhoid+hepatitis A 43 (14.6)





Typhoid-hepatitis A 94 (3.6)

















*Sex available for n=73 837 participants.
†Indigenous status available for n=58 145 participants.
‡Pregnancy status available for n=72 951 participants (SmartVax only).
§The percentages listed under ‘concomitant vaccines’ are the percentage of 
all concomitant vaccine(s) administered per group.
¶+ indicates two separate vaccines administered concomitantly.
**Pregnant participants are also included in their respective age categories 
(age range: 15–49 years).
23vPPV, 23-valent pneumococcal polysaccharide vaccine; DTPa,  Diphtheria 
tetanus acellular pertussis (for children aged <10 years); DTPa-IPV, DTPa-
inactivated polio vaccine (for children aged <10 years); dTpa, diphtheria 
tetanus acellular pertussis (for individuals aged ≥10 years); dTpa-IPV, dTpa-
inactivated polio vaccine (for individuals aged ≥10 years); HibMenCCV, 
Haemophilus influenzae type B meningococcal C conjugate vaccine; 
HPV, human papillomavirus; MenBV, meningococcal B vaccine; MMR, 
measles, mumps and rubella; MMRV, measles, mumps, rubella and varicella. 
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asked whether or not the event was medically attended. 
‘Yes’ responders were asked to detail the adverse event(s) 
and/or medical attention in a short online survey, which 
listed a range of symptoms and asked participants to tick 
all symptoms experienced. As children aged 6 months to 
8 years and immunocompromised individuals of any age 
are recommended to receive two vaccine doses at least 
4 weeks apart when first immunised, some may have been 
represented by more than one record.
Primary outcomes surveyed were reports of any event 
(yes or no), fever (solicited in the online survey) and 
MA (yes or no). Secondary outcomes (solicited in the 
online survey) were injection site (IS) pain, swelling and/
or redness; tiredness/fatigue; headache; sleep pattern 
change; irritability; rash; vomiting; diarrhoea; rigours; 
non-responsiveness/loss of consciousness; and convul-
sions/seizures. Unsolicited symptoms were detailed by 
participants in free text.
Detailed clinical data from MAs were sought using 
additional information from participants’ immunisa-
tion providers and/or by a public health authority, who 
attempted to contact participants/caregivers to ascer-
tain whether or not MAs were serious (as defined by the 
Australian Therapeutic Goods Administration).12
Patient involvement
The AusVaxSafety surveillance system does not specifi-
cally recruit patients but does rely on community partic-
ipation. The majority of participants are included in the 
surveillance system because their primary care provider 
or immunisation clinic has installed the SmartVax data 
monitoring platform, which functions in conjunction 
with the clinic software. Where installed, SmartVax auto-
matically sends text messages to all patients who receive 
any vaccine to seek information regarding any AEFI as 
a routine part of patient management and aftercare. In 
this study, we report only on patient responses regarding 
influenza vaccine. A small proportion of participant 
data are provided to AusVaxSafety via the Vaxtracker 
or STARSS data monitoring platforms which similarly 
survey individuals who have received an influenza vacci-
nation from a participating provider or clinic. The data 
monitoring platforms were piloted and developed with 
feedback from users. The AusVaxSafety surveillance 
system Advisory Committee includes a consumer/patient 
representative. Surveillance results are uploaded to the 
AusVaxSafety website (www. ausvaxsafety. org. au) weekly 
and available to the public.
near real-time reporting and analysis
Deidentified records (including demographic, immunisa-
tion visit and SMS/survey response data) were uploaded 
to the computer-based monitoring systems and exported 
weekly to the AusVaxSafety coordinating centre for 
aggregation and analysis. MA reports triggered clinical 
follow-up by designated public health authorities each 
weekday. Weekly analysis of cumulative data (received 
up to 5 days prior) for age and pregnancy-specific AEFI 
rates and participant demographic characteristics were 
reported in detail to the Australian Department of Health 
and summary results were published online each Friday 
(www. ausvaxsafety. org. au) from week 3 of surveillance for 
the duration of the surveillance period.
Weekly signal detection
Participant-reported rates of fever (for those aged 6 
months to 4 years) and MA (for all participants, grouped 
by age: 6 months to 4 years, 5–64 years and ≥65 years; 
and pregnant participants) as a surrogate for serious 
adverse events (SAE)7 were considered the most objective 
outcome measures of vaccine safety and were monitored 
weekly using signal detection methods.
Fast initial response cumulative summation (FIR 
CUSUM) control charts monitored log-likelihood ratios 
of each event rate being at a maximum acceptable level 
versus expected level.13 Expected and maximum accept-
able rates were set based on syntheses of clinical trial data 
and previous surveillance results.6 7 10 14–16 The expected 
MA rate was set at 1%, and the expected fever rate at 3%. 
Maximum acceptable rates were set at 3% and 10% for 
MA and fever, respectively. A safety signal is generated if 
the log-likelihood ratio (a measure of the degree to which 
the data are more consistent with an event rate equal 
to the maximum acceptable rate vs the expected rate) 
Table 2 Adverse event rates for influenza vaccine, by age group and pregnancy status
Type of adverse 
event*
Group (n/N (%))
6 months to 















































*Denominators differ between any adverse event/medical attendance and fever because reports of fever are solicited in an online survey following the 
initial short message service (SMS) regarding an adverse event following immunisation (AEFI), and not all participants complete the survey.
†Pregnant participants are also included in their respective age categories (age range: 15–49 years). They are not compared with another group in this 
table.
‡P<0.001 for participants aged 6 months to 4 years compared with all other age groups.
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rises above a predetermined threshold. The threshold 
log-likelihood ratio was selected such that across 10 000 
simulated vaccination seasons there would be ≥80% prob-
ability of signal generation within 3 weeks of commence-
ment if the event rate is at the maximum acceptable level, 
and ≤2% probability of (false) signal generation over the 
entire season when the event rate is at the expected level.
Bayesian analysis was also performed weekly for robust, 
optimal estimation of the 95% credibility interval (CI) 
for true cumulative event rates. Beta distributions with 
means derived from 2016 surveillance data and literature 
review (MA: 1% for participants aged 6 months to 4 years; 
0.3% for participants aged 5–64 years and ≥65 years; 1% 
for pregnant participants; and fever: 3% for participants 
aged 6 months to 4 years)7 were used as priors at the start 
of the 2017 season. Priors were updated with each week’s 
observed data and CIs from the posterior beta distribu-
tion were reported weekly.
end-of-surveillance cumulative analysis
Cumulative data were reported by epidemiological week 
and demographic information including age (6 months 
to 4 years, 5–14 years, 15–39 years, 40–64 years and ≥65 
years), sex, pregnancy status (available for SmartVax 
participants only), Aboriginal and/or Torres Strait 
Islander (hereafter referred to as Indigenous) status and 
concomitant vaccine administration (defined as any addi-
tional vaccine(s) received at the same visit as influenza 
vaccine).
For any adverse event, fever and MA, rates were calcu-
lated for each age group and pairwise proportion tests 
with Holm adjustment for multiple comparisons were 
performed to compare AEFI rates between pairs of age 
groups using R V.3.4.2 (R Foundation for Statistical 
Computing, Vienna, Austria). AEFI rates in pregnant 
women were compared with those of non-pregnant 
female SmartVax participants of the same age range 
(15–49 years) using Pearson’s Χ2 test in Stata V.14.2 
(StataCorp, College Station, TX, USA). Rates of primary 
and secondary outcomes were calculated by brand, and 
secondary outcomes were calculated for each age group 
and pregnant women.
Primary outcome AEFI rates were also calculated for 
age groups and pregnant women by vaccine brand and 
concomitant vaccine receipt (yes or no). The relative risk 
of each adverse event was compared for those receiving 
influenza vaccine plus any concomitant vaccine(s) 
versus influenza vaccine alone, and for those receiving 
FluQuadri versus Fluarix Tetra, using a generalised linear 
model with a log link and binomial distribution in Stata 
V.14.2.
results
Weekly signal detection throughout 2017
No safety signals were detected by the FIR CUSUM 
method (online supplementary efigure 1). Weekly and 
cumulative Bayesian rates of fever and MA remained well 
below their respective maximum acceptable rates over the 
surveillance period: the cumulative (end-of-season) fever 
rate in children aged 6 months to 4 years was 2.3% (95% 
posterior CI 2.0 to 2.7), while cumulative MA rates were 
1.0% (95% CI 0.73 to 1.21) in children aged 6 months to 
4 years, 0.5% (95% CI 0.41 to 0.55) in participants aged 
5–64 years, 0.3% (95% CI 0.22 to 0.34) in participants 
aged ≥65 years and 0.5% (95% CI 0.26 to 0.87) in preg-
nant women. For those MAs that were followed up, none 
of these events were categorised as serious.
end-of-surveillance analysis
Over the surveillance period, 73 892 of 102 911 enrollees 
(71.8%) responded to the postvaccination SMS; over 95% 
of participants with response time available (n=71 093) 
responded on the same day of SMS receipt. Partici-
pants received one of four available QIIVs: Fluarix Tetra 
(GlaxoSmithKline; 45.3%), FluQuadri (Sanofi-Aventis; 
42.3%), FluQuadri Junior (Sanofi-Aventis; 5.6%) or 
Afluria Quad (Seqirus; 6.8%); less than 1.0% received a 
vaccine whose brand could not be determined. Half of 
all vaccines were administered within 5 weeks of starting 
surveillance, with older participants (≥65 years) receiving 
vaccines earlier compared with young children (6 months 
to 4 years old) and pregnant women (figure 1).
Among all participants, 58.1% were female and the 
median age was 57 years (range: 6 months to 102 years). 
Two per cent (1156/58 145 with data available) were 
Indigenous, which is representative of the Australian 
national Aboriginal and/or Torres Strait Islander popu-
lation (2.8%) (table 1). Among female participants aged 
15–49 years for whom pregnancy status was available 
(98.6%), 15.2% (2018/13 242) were pregnant. Individ-
uals aged ≥65 years represented the largest proportion 
of participants (38.1%; 33.6% aged 65–79 years and 
4.5% aged ≥80 years). Approximately 14% of partici-
pants (10 428/73 892) received a concomitant vaccine, 
of which 86.6% received only one. The most commonly 
received concomitant vaccines are listed in table 1.
Compared with other age groups, children aged 6 
months to 4 years were reported as having significantly 
higher rates of any adverse event, while participants 
aged ≥65 years reported events less often (table 2). Preg-
nant women reported significantly lower rates of any 
adverse event compared with non-pregnant women of the 
same age range (15–49 years; p=0.019, data not shown). 
Rates of more subjective secondary outcomes surveyed 
showed similar trends across age groups and by preg-
nancy status (online supplementary etable 1).
Participants who received concomitant vaccine(s) 
had an elevated risk of reporting any adverse event and 
fever compared with participants who received influenza 
vaccine alone (table 3). This pattern was seen for all age 
groups, with the exception of fever in participants aged 
15–39 years and pregnant women. Participants aged ≥40 
years who received concomitant vaccine(s) reported MA 
at a significantly higher rate than those who received only 
an influenza vaccine.
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Brand-specific AEFI rates were similar, particularly for 
FluQuadri and Fluarix Tetra, the brands administered to 
the majority of participants (table 4, online supplemen-
tary etable 2).
DIsCussIOn
AusVaxSafety surveillance used almost 74 000 actively 
solicited participant-reported outcomes to demonstrate 
that the four brands of QIIV used in Australia in 2017 
were safe and had low and comparable adverse event rates 
within expected ranges for all age groups and pregnant 
women.10 14–16 This novel system provided reassuring, 
locally derived feedback on vaccine safety in near real 
time to the public and immunisation providers as influ-
enza vaccination was rolled out across Australia.17
Consistent with data published from vaccine clinical 
trials, the most common participant-reported event 
following influenza immunisation was IS pain (1.7% 
overall). IS pain was also commonly reported in clinical 
trials, but at higher rates than those demonstrated in this 
postmarketing surveillance. Clinical trials in children 
reported IS pain in approximately two-thirds of those 
aged 3–17 years18 with similarly high rates (up to 72.4%) 
in adults aged 18–60 years.19 20 This difference is likely 
due to more active solicitation of AEFI in clinical trials via 
daily diary cards, resulting in more complete reporting. 
Also, as AusVaxSafety participants may be informed of 
expected common vaccine reactions by their clinicians, 
these symptoms may be less likely to be reported. By 
comparison, data from both this postmarketing surveil-
lance and clinical trials confirmed low rates of SAEs (0.4% 
for AusVaxSafety compared with 0.0%–2.3% for the clin-
ical trials), despite differences in SAE definitions. Equally 
reassuring, both IS pain rates and SAEs among pregnant 
women in our surveillance were low and consistent with 
rates reported among participants of all ages.
Adverse event rates were similar for Fluarix Tetra 
(GlaxoSmithKline) and FluQuadri (Sanofi-Aventis), the 
two most used QIIVs in Australia in 2017. Though small 
and variable differences in AEFI rates between brands 
were reported, this is likely attributable to factors such 
as age and uncontrolled confounding, and is not of clin-
ical significance. Ongoing brand-specific surveillance will 
provide valuable safety data in future years, especially as 
two new, more immunogenic vaccine types—the high 
dose TIIV (Fluzone High-Dose, Sanofi-Aventis) and the 
MF-59 adjuvanted influenza vaccine (Fluad, Seqirus)—
are being included on the Australian NIP for adults 
aged ≥65 years from 2018.21
We previously observed that AusVaxSafety participants 
aged 6 months to 4 years who received influenza vaccine 
and another vaccine concomitantly (in particular diph-
theria-tetanus-acellular pertussis (DTPa) inactivated 
poliovirus or meningococcal B vaccines) had significantly 
increased AEFI rates (especially fever) compared with 
those receiving influenza vaccine alone.6 7 The present 
analysis showed that AEFI were more common with 
concomitant vaccination among participants of all ages, 
including increased fever rates in both children and older 
adults and an increased risk of MA among those aged ≥40 
years. The most commonly received concomitant vaccines 
were 23-valent pneumococcal vaccine, reduced antigen 
pertussis-containing vaccine (dTpa) and live attenuated 
zoster vaccine, which are reactogenic when administered 
individually.22–28 It has been shown that concomitant 
receipt of influenza and 13-valent pneumococcal vaccines 
results in increased local and systemic events, including 
fever among children,29–31 while such differences in AEFI 
rates were not observed with concomitant receipt of influ-
enza and pertussis or zoster vaccines.32–35 Importantly, 
the increased risks of AEFI occurring with concomitant 
vaccination reported by AusVaxSafety—including those 
requiring MA—were low and likely not of clinical impor-
tance. This information may help providers to reassure 
patients who are receiving more than one vaccine at the 
same time that although they may have a slightly higher 
rate of side effects, the absolute rate is low overall. As more 
vaccines become available, assessment of adverse events 
associated with concomitant vaccination using surveil-
lance like AusVaxSafety has the potential to contribute 
valuable detail to postmarketing pharmacovigilance.
To the best of our knowledge, AusVaxSafety is a unique 
postmarketing vaccine safety surveillance system in its 
high level of automation, patient and provider engage-
ment and ability to provide data on vaccine brand-spe-
cific AEFI rates in near real time. However, since the 
EMA recommendation to provide annual brand-spe-
cific safety data, there has been an increase in pilot and 
feasibility studies of influenza vaccine safety surveillance 
methods and systems.36–40 Several are enhanced passive 
surveillance systems relying on patients returning adverse 
event reports via cards or telephone.36 38 Such systems 
are limited by potential under-reporting of events and 
are likely slower and more resource intensive as staff 
must enter AEFI details or conduct interviews. The Cana-
dian National Vaccine Safety Network has conducted a 
small pilot of a mobile phone app for reporting adverse 
events.40 Eighty-six per cent of those replying to questions 
about the usability of an app for reporting AEFI said they 
would prefer an app to visiting a website. Nevertheless, 
investigators acknowledged that the app was limited 
by download requirements and low survey completion 
rates. The US Centers for Disease Control and Preven-
tion’s Vaccine Safety Datalink (VSD), which uses large 
linked databases from healthcare organisations, conducts 
Rapid Cycle Analysis (RCA) to report AEFI rates in near 
real time but may be limited by delays between AEFI 
occurrence and electronic reporting to administra-
tive data sets. VSD’s surveillance compares outcomes of 
interest in those who received the vaccine against the 
same outcomes experienced by a group of individuals 
who did not receive the vaccine (or in a control period for 
the vaccine recipient for self-controlled case series).41 42 
While AusVaxSafety does not currently monitor some of 
the more severe adverse events that the VSD’s RCA may 
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detect (particularly those occurring more than 3 days 
following vaccination), AusVaxSafety’s strength comes 
from its ability to quickly estimate the number of vaccine 
recipients who have (or have not) experienced an AEFI 
without relying on complex analytical methods.
There are several limitations of AusVaxSafety surveil-
lance and the analysis in this report. First, self-report 
or parent/carer reports of outcomes gathered through 
participant-based feedback may be less accurate for 
common and expected reactions than those solicited 
from clinical trial participants or those detected by 
systems like the VSD. Second, though we have attempted 
to adjust for potential biases by reporting the more objec-
tive outcomes of MA and fever, it should be noted that 
participant-reported fever is subjective and has not been 
confirmed. Also, should a very serious event, such as 
death, occur after immunisation, an individual may not 
be capable of participating in AusVaxSafety surveillance; 
the system may therefore not identify the most SAEs. 
Third, not all adverse events are vaccine attributable, 
and AEFI rates may be affected by other illnesses with 
similar outcomes, for example, fever from intercurrent 
viral illness. Finally, in this report, data did not allow for 
comparisons of the reactogenicity of each non-influenza 
vaccine administered alone, and therefore conclusions 
made about increased adverse event rates associated with 
concomitant vaccination must be tempered. As AusVax-
Safety expands to include safety surveillance for more 
vaccines, the system’s capacity to make such compari-
sons and provide data on the reactogenicity of more and 
varied vaccines will be enhanced.
In its requirement that annual enhanced postauthori-
sation influenza vaccine safety monitoring occur for all 
seasonal influenza vaccines, the EMA stated a preference 
for active surveillance.2 Data in this report and for other 
vaccines in the AusVaxSafety system (including pertussis, 
human papillomavirus and herpes zoster vaccines17) 
from hundreds of thousands of vaccinated participants 
since 2014 demonstrate the value of active vaccine safety 
surveillance systems. Age and brand-specific AEFI rates 
are available within weeks of the commencement of each 
year’s seasonal influenza immunisation programme, 
which ensure early detection of potential safety signals. 
This includes 2018 Southern Hemisphere seasonal influ-
enza vaccines, for which data from more than 140 000 
influenza vaccine recipients vaccinated between April 
and June 2018 demonstrate no safety concerns (data not 
shown, but available in summary form at www. ausvax-
safety. org. au).
Australia also has a comprehensive national passive 
vaccine safety surveillance system.43 However, all passive 
or spontaneous reporting systems have inherent limita-
tions, including incomplete and under-reporting, stim-
ulated reporting and limited data on vaccine brands. 
Importantly, with passive systems, it is often difficult to 
determine AEFI rates due to lack of denominator data 
on vaccines administered. In Australia, these limitations 
have especially affected passive influenza vaccine safety 
surveillance, and have led to previous difficulty in inter-
preting early or potential vaccine safety signals.44 In this 
context, AusVaxSafety provides important data to ensure 
confidence in the safety of vaccines in use in large popu-
lations in near real time.
COnClusIOns
Approximately 74 000 influenza vaccine recipients 
reported low adverse event rates following immunisa-
tion with the four brands of QIIV used in Australia in 
2017. Concomitant vaccination was associated with an 
increased AEFI risk, but rates were still low and within 
expected ranges. Our novel participant-based postmar-
keting vaccine safety surveillance system is a valuable tool 
for monitoring immunisation, especially for annually 
changing influenza vaccines.
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